Hide metadata

dc.date.accessioned2018-03-21T14:55:04Z
dc.date.available2018-03-21T14:55:04Z
dc.date.created2017-10-11T16:42:07Z
dc.date.issued2017
dc.identifier.citationRodriguez, Marta Bajo-Santos, Cristina Hessvik, Nina Pettersen Lorenz, Susanne Fromm, Bastian Berge, Viktor Sandvig, Kirsten Line, Aija Llorente, Alicia . Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes. Molecular Cancer. 2017, 16, 156
dc.identifier.urihttp://hdl.handle.net/10852/61215
dc.description.abstractThe aim of this study was to identify microRNAs in urinary exosomes that are differently expressed in prostate cancer patients and healthy donors. For this purpose, RNA was extracted from urinary exosomes from 20 prostate cancer patients and 9 healthy males and the microRNAs were analyzed by next generation sequencing. Interestingly, 5 microRNAs – miR-196a-5p, miR-34a-5p, miR-143-3p, miR-501-3p and miR-92a-1-5p – were significantly downregulated in exosomes from prostate cancer patients. Furthermore, RT-qPCR analysis of an independent cohort of 28 prostate cancer patients and 19 healthy males confirmed that miR-196a-5p and miR-501-3p were downregulated in prostate cancer samples. These results suggest that specific microRNAs in urinary exosomes might serve as non-invasive biomarkers for prostate cancer. In particular, miR-196a-5p and miR-501-3p are promising biomarkers that need to be further studied in large patient cohorts.en_US
dc.languageEN
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleIdentification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomesen_US
dc.typeJournal articleen_US
dc.creator.authorRodriguez, Marta
dc.creator.authorBajo-Santos, Cristina
dc.creator.authorHessvik, Nina Pettersen
dc.creator.authorLorenz, Susanne
dc.creator.authorFromm, Bastian
dc.creator.authorBerge, Viktor
dc.creator.authorSandvig, Kirsten
dc.creator.authorLine, Aija
dc.creator.authorLlorente, Alicia
cristin.unitcode185,53,2,10
cristin.unitnameSenter for kreftbiomedisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin1503908
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Molecular Cancer&rft.volume=16&rft.spage=156&rft.date=2017
dc.identifier.jtitleMolecular Cancer
dc.identifier.volume16
dc.identifier.startpage156
dc.identifier.doihttp://dx.doi.org/10.1186/s12943-017-0726-4
dc.identifier.urnURN:NBN:no-63859
dc.type.documentTidsskriftartikkelen_US
dc.type.peerreviewedPeer reviewed
dc.source.issn1476-4598
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/61215/1/Mol.Cancer%2B2017%2BRodriguez.pdf
dc.type.versionPublishedVersion
dc.relation.projectNFR/179571


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International